| Jayson Scott Greenberg, MD | |
|
7500 Challis Rd, 1st Floor, Brighton, MI 48116-9416 | |
| (810) 263-4000 | |
| Not Available |
| Full Name | Jayson Scott Greenberg |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 7500 Challis Rd, Brighton, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538197173 | NPI | - | NPPES |
| 10-20013 | Other | MI | PHYSICIAN HEALTH PLAN UHC |
| 4405491-10 | Medicaid | MI | |
| 0403811832 | Other | MI | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 4301078781 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
Chronic pain involves more than just hurting. People suffering from pain often experience sadness, depression and lethargy. That's one reason opioids can be so addictive - they not only dampen the pain but also make people feel euphoric.
Long non-coding RNAs (lncRNA) are unusual in that they don't encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 6 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
Chronic pain involves more than just hurting. People suffering from pain often experience sadness, depression and lethargy. That's one reason opioids can be so addictive - they not only dampen the pain but also make people feel euphoric.
Long non-coding RNAs (lncRNA) are unusual in that they don't encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 6 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326307489 PECOS PAC ID: 3779496856 Enrollment ID: O20031117000199 |
News Archive
Chronic pain involves more than just hurting. People suffering from pain often experience sadness, depression and lethargy. That's one reason opioids can be so addictive - they not only dampen the pain but also make people feel euphoric.
Long non-coding RNAs (lncRNA) are unusual in that they don't encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 6 days ago
| Entity Name | W.a. Foote Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760437826 PECOS PAC ID: 0244136067 Enrollment ID: O20031212000691 |
News Archive
Chronic pain involves more than just hurting. People suffering from pain often experience sadness, depression and lethargy. That's one reason opioids can be so addictive - they not only dampen the pain but also make people feel euphoric.
Long non-coding RNAs (lncRNA) are unusual in that they don't encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jayson Scott Greenberg, MD 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | Jayson Scott Greenberg, MD 7500 Challis Rd, 1st Floor, Brighton, MI 48116-9416 Ph: (810) 263-4000 |
News Archive
Chronic pain involves more than just hurting. People suffering from pain often experience sadness, depression and lethargy. That's one reason opioids can be so addictive - they not only dampen the pain but also make people feel euphoric.
Long non-coding RNAs (lncRNA) are unusual in that they don't encode proteins like normal RNA. Yet they do play a role in regulating cellular functions and interest cancer researchers.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.
Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.
› Verified 6 days ago